Adalimumab in Vogt-Koyanagi-Harada Disease Refractory to Conventional Therapy

Background: No study explores the effectiveness of adalimumab in sight-threatening Vogt-Koyanagi-Harada (VKH) patients in China. Objective: To evaluate the short-term effectiveness and safety of adalimumab (ADA) in patients with sight-threatening Vogt-Koyanagi-Harada (VKH) disease refractory to conv...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Shizhao, Tao, Tianyu, Huang, Zhaohao, Liu, Xiuxing, Li, He, Xie, Lihui, Wen, Feng, Chi, Wei, Su, Wenru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789678/
https://www.ncbi.nlm.nih.gov/pubmed/35096888
http://dx.doi.org/10.3389/fmed.2021.799427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789678/
https://www.ncbi.nlm.nih.gov/pubmed/35096888
http://dx.doi.org/10.3389/fmed.2021.799427

Ejemplares similares